{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:56:26Z","timestamp":1773485786608,"version":"3.50.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s11926-008-0038-1","type":"journal-article","created":{"date-parts":[[2008,10,23]],"date-time":"2008-10-23T19:02:25Z","timestamp":1224788545000},"page":"235-248","source":"Crossref","is-referenced-by-count":13,"title":["Non-crystalline and crystalline rheumatic disorders in chronic kidney disease"],"prefix":"10.1007","volume":"10","author":[{"given":"Pasha","family":"Sarraf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Reginato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,24]]},"reference":[{"key":"38_CR1","first-page":"247","volume":"18","author":"E.A. Brown","year":"1982","unstructured":"Brown EA, Gower PE: Joint problems in patients on maintenance hemodialysis. Clin Nephrol 1982, 18:247\u2013250.","journal-title":"Clin Nephrol"},{"key":"38_CR2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0002-9343(85)90466-8","volume":"78","author":"S. Goldstein","year":"1985","unstructured":"Goldstein S, Winston E, Chung TJ, et al.: Chronic arthropathy in long-term hemodialysis. Am J Med 1985, 78:82\u201386.","journal-title":"Am J Med"},{"key":"38_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-008-0033-6","volume":"10","author":"D. Todd","year":"2008","unstructured":"Todd D, Kay J: Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Cur Rheum Rep 2008 10:195\u2013204.","journal-title":"Cur Rheum Rep"},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1152\/japplphysiol.00564.2003","volume":"95","author":"E. Seeman","year":"2003","unstructured":"Seeman E: Invited review: Pathogenesis of osteoporosis. J Appl Physiol 2003, 95:2142\u20132151.","journal-title":"J Appl Physiol"},{"key":"38_CR5","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E. Seeman","year":"2006","unstructured":"Seeman E, Delmas PD: Bone quality\u2014the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250\u20132261.","journal-title":"N Engl J Med"},{"key":"38_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1753-4887.2001.tb06957.x","volume":"59","author":"R.P. Heaney","year":"2001","unstructured":"Heaney RP: The bone remodeling transient: interpreting interventions involving bone-related nutrients. Nutr Rev 2001, 59:327\u2013334.","journal-title":"Nutr Rev"},{"key":"38_CR7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S8756-3282(03)00218-7","volume":"33","author":"R.P. Heaney","year":"2003","unstructured":"Heaney RP: How does bone support calcium homeostasis? Bone, 2003, 33:264\u2013268.","journal-title":"Bone"},{"key":"38_CR8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S8756-3282(03)00236-9","volume":"33","author":"R.P. Heaney","year":"2003","unstructured":"Heaney RP: Is the paradigm shifting? Bone 2003, 33:457\u2013465.","journal-title":"Bone"},{"key":"38_CR9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bone.2007.06.010","volume":"41","author":"E. Seeman","year":"2007","unstructured":"Seeman E: Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 2007, 41:308\u2013317.","journal-title":"Bone"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1359\/jbmr.2002.17.12.2094","volume":"17","author":"G. Elder","year":"2002","unstructured":"Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002, 17:2094\u20132105.","journal-title":"J Bone Miner Res"},{"key":"38_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11926-005-0009-8","volume":"7","author":"P.D. Miller","year":"2005","unstructured":"Miller PD: Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists. Curr Rheumatol Rep 2005, 7:53\u201360.","journal-title":"Curr Rheumatol Rep"},{"key":"38_CR12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/14740338.6.6.663","volume":"6","author":"E.M. Lewiecki","year":"2007","unstructured":"Lewiecki EM, Miller PD: Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf 2007, 6:663\u2013672.","journal-title":"Expert Opin Drug Saf"},{"key":"38_CR13","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1371\/journal.pbio.0020348","volume":"2","author":"J.R. Zierath","year":"2004","unstructured":"Zierath JR, Hawley JA: Skeletal muscle fiber type: influence on contractile and metabolic properties. PLoS Biol 2004, 2:e348.","journal-title":"PLoS Biol"},{"key":"38_CR14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.jrn.2004.09.022","volume":"15","author":"J.D. Kopple","year":"2005","unstructured":"Kopple JD, Storer T, Casburi R, et al.: Impaired exercise capacity and exercise training in maintenance hemodialysis patients. J Ren Nutr 2005, 15:44\u201348.","journal-title":"J Ren Nutr"},{"key":"38_CR15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/ndt\/gfh784","volume":"20","author":"T.W. Storer","year":"2005","unstructured":"Storer TW, Casaburi R, Sawelson S, Kopple JD: Endurance exercise training during haemodialysis improves strength, power, fatigability and physical performance in maintenance haemodialysis patients. Nephrol Dial Transplant 2005, 20:1429\u20131437.","journal-title":"Nephrol Dial Transplant"},{"key":"38_CR16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000090221","volume":"103","author":"A.P. Harrison","year":"2006","unstructured":"Harrison AP, Nielsen AH, Eidemak I, et al.: The uremic environment and muscle dysfunction in man and rat. Nephron Physiol 2006, 103:33\u201342.","journal-title":"Nephron Physiol"},{"key":"38_CR17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1046\/j.1523-1755.2002.00614.x","volume":"62","author":"J.M. Campistol","year":"2002","unstructured":"Campistol JM: Uremic myopathy. Kidney Int 2002, 62:1901\u20131913.","journal-title":"Kidney Int"},{"key":"38_CR18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1210\/er.2006-0037","volume":"27","author":"C. Handschin","year":"2006","unstructured":"Handschin C, Spiegelman BM: Peroxisome proliferatoractivated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006, 27:728\u2013735.","journal-title":"Endocr Rev"},{"key":"38_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1096\/fj.03-0610com","volume":"18","author":"S.H. Lecker","year":"2004","unstructured":"Lecker SH, Jagoe RT, Gilbert A, et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004, 18:39\u201351.","journal-title":"FASEB J"},{"key":"38_CR20","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1096\/fj.02-0312com","volume":"16","author":"R.T. Jagoe","year":"2002","unstructured":"Jagoe RT, Lecker SH, Gomes M, Goldberg AL: Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J 2002, 16:1697\u20131712.","journal-title":"FASEB J"},{"key":"38_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","volume":"117","author":"M. Sandri","year":"2004","unstructured":"Sandri M, Sandri C, Gilbert A, et al.: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399\u2013412.","journal-title":"Cell"},{"key":"38_CR22","first-page":"3940","volume":"117","author":"J. Hanai","year":"2007","unstructured":"Hanai J, Cao P, Tanksale P, et al.: The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007, 117:3940\u20133951.","journal-title":"J Clin Invest"},{"key":"38_CR23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa070447","volume":"358","author":"S. Levine","year":"2008","unstructured":"Levine S, Nguyen T, Taylor N, et al.: Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008, 358:1327\u20131335.","journal-title":"N Engl J Med"},{"key":"38_CR24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cmet.2007.11.001","volume":"6","author":"C. Mammucari","year":"2007","unstructured":"Mammucari C, Milan G, Romanello V, et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Met 2007, 6:458\u2013471.","journal-title":"Cell Met"},{"key":"38_CR25","first-page":"45","volume":"26","author":"N. Raben","year":"2007","unstructured":"Raben N, Roberts A, Plotz PH: Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007, 26:45\u201348.","journal-title":"Acta Myol"},{"key":"38_CR26","doi-asserted-by":"crossref","first-page":"16260","DOI":"10.1073\/pnas.0607795103","volume":"103","author":"M. Sandri","year":"2006","unstructured":"Sandri M, Lin J, Handschin C, et al.: PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 2006, 103:16260\u201316265.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38_CR27","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1172\/JCI34022","volume":"118","author":"J.C. Bruusgaard","year":"2008","unstructured":"Bruusgaard JC, Gundersen K: In vivo time-lapse microscopy reveals no loss of murine myonuclei during weeks of muscle atrophy. J Clin Invest 2008, 118:1450\u20131457.","journal-title":"J Clin Invest"},{"key":"38_CR28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.cellbio.20.012103.135836","volume":"20","author":"S.J. Lee","year":"2004","unstructured":"Lee SJ: Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004, 20:61\u201386.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"38_CR29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1210\/en.2006-0539","volume":"148","author":"H. Gilson","year":"2007","unstructured":"Gilson H, Schakman O, Combaret L, et al.: Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007, 148:452\u2013460.","journal-title":"Endocrinology"},{"key":"38_CR30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.ki.5001532","volume":"70","author":"D.F. Sun","year":"2006","unstructured":"Sun DF, Chen Y, Rabkin R: Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 2006, 70:453\u2013459.","journal-title":"Kidney Int"},{"key":"38_CR31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.ki.5001622","volume":"70","author":"R.H. Mak","year":"2006","unstructured":"Mak RH, Rotwein P: Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation. Kidney Int 2006, 70:410\u2013412.","journal-title":"Kidney Int"},{"key":"38_CR32","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","volume":"296","author":"T.A. Zimmers","year":"2002","unstructured":"Zimmers TA, Davies MV, Koniaris LG, et al.: Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296:1486\u20131488.","journal-title":"Science"},{"key":"38_CR33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s002230010085","volume":"66","author":"H. Glerup","year":"2000","unstructured":"Glerup H, Mikkelsen K, Poulsen L, et al.: Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 2000, 66:419\u2013424.","journal-title":"Calcif Tissue Int"},{"key":"38_CR34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.20713","volume":"35","author":"A.V. Krishnan","year":"2007","unstructured":"Krishnan AV, Kiernan MC: Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007, 35:273\u2013290.","journal-title":"Muscle Nerve"},{"key":"38_CR35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.1985.190","volume":"28","author":"R. Baczynski","year":"1985","unstructured":"Baczynski R, Massry SG, Magott M, et al.: Effect of parathyroid hormone on energy metabolism of skeletal muscle. Kidney Int 1985, 28:722\u2013727.","journal-title":"Kidney Int"},{"key":"38_CR36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ncprheum0700","volume":"4","author":"G. Riley","year":"2008","unstructured":"Riley G: Tendinopathy\u2014from basic science to treatment. Nat Clin Pract Rheumatol 2008, 4:82\u201389.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"38_CR37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1749-6632.1999.tb07688.x","volume":"878","author":"A.H. Drummond","year":"1999","unstructured":"Drummond AH, Beckett P, Brown PD, et al.: Preclinical and clinical studies of inhibitors in cancer. Ann N Y Acad Sci 1999, 878:228\u2013235.","journal-title":"Ann N Y Acad Sci"},{"key":"38_CR38","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1002\/art.10617","volume":"46","author":"A.N. Corps","year":"2002","unstructured":"Corps AN, Harrall RL, Curry VA, et al.: Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum 2002, 46:3034\u20133040.","journal-title":"Arthritis Rheum"},{"key":"38_CR39","first-page":"756","volume":"72","author":"B. Pasternak","year":"2006","unstructured":"Pasternak B, Fellenius M, Aspenberg P: Doxycycline impairs tendon repair in rats. Acta Orthop Belg 2006, 72:756\u2013760.","journal-title":"Acta Orthop Belg"},{"key":"38_CR40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1073\/pnas.0707069105","volume":"105","author":"C.L. Mendias","year":"2008","unstructured":"Mendias CL, Bakhurin KI, Faulkner JA: Tendons of myostatin-deficient mice are small, brittle, and hypocellular. Proc Natl Acad Sci U S A 2008, 105:388\u2013393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38_CR41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5414\/CNP58118","volume":"58","author":"M.K. Shah","year":"2002","unstructured":"Shah MK: Simultaneous bilateral quadriceps tendon rupture in renal patients. Clin Nephrol 2002, 58:118\u2013121.","journal-title":"Clin Nephrol"},{"key":"38_CR42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.cps.2005.05.004","volume":"32","author":"Y. Khaliq","year":"2005","unstructured":"Khaliq Y, Zhanel GG: Musculoskeletal injury associated with fluoroquinolone antibiotics. Clin Plast Surg 2005, 32:495\u2013502.","journal-title":"Clin Plast Surg"},{"key":"38_CR43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.mnh.0000168336.67499.c0","volume":"14","author":"G.M. London","year":"2005","unstructured":"London GM, Marchais SJ, Gu\u00e9rin AP, M\u00e9tivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005, 14:525\u2013531.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"38_CR44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/bj1020053","volume":"102","author":"D.W. Moss","year":"1967","unstructured":"Moss DW, Eaton RH, Smith JK, Whitby LG: Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J 1967, 102:53\u201357.","journal-title":"Biochem J"},{"key":"38_CR45","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.1780370624","volume":"37","author":"R. Terkeltaub","year":"1994","unstructured":"Terkeltaub R, Rosenbach M, Fong F, Goding J: Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum 1994, 37:934\u2013941.","journal-title":"Arthritis Rheum"},{"key":"38_CR46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1126\/science.289.5477.265","volume":"289","author":"A.M. Ho","year":"2000","unstructured":"Ho AM, Johnson MD, Kingsley DM: Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265\u2013270.","journal-title":"Science"},{"key":"38_CR47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/ng1221","volume":"34","author":"F. Rutsch","year":"2003","unstructured":"Rutsch F, Ruf N, Vaingankar S, et al.: Mutations in ENPP1 are associated with \u2018idiopathic\u2019 infantile arterial calcification. Nat Genet 2003, 34:379\u2013381.","journal-title":"Nat Genet"},{"key":"38_CR48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ndt\/gfm566","volume":"23","author":"P. Eller","year":"2008","unstructured":"Eller P, Hochegger K, Feuchtner GM, et al.: Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant 2008, 23:321\u2013327.","journal-title":"Nephrol Dial Transplant"},{"key":"38_CR49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1523-1755.2001.00803.x","volume":"60","author":"A.R. Mazhar","year":"2001","unstructured":"Mazhar AR, Johnson RJ, Gillen D, et al.: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001, 60:324\u2013332.","journal-title":"Kidney Int"},{"key":"38_CR50","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1681\/ASN.2004080694","volume":"16","author":"K.A. Lomashvili","year":"2005","unstructured":"Lomashvili KA, Khawandi W, O\u2019Neill WC: Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005, 16:2495\u20132500.","journal-title":"J Am Soc Nephrol"},{"key":"38_CR51","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1074\/jbc.M109683200","volume":"277","author":"A.F. Zebboudj","year":"2002","unstructured":"Zebboudj AF, Imura M, Bostr\u00f6m K: Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002, 277:4388\u20134394.","journal-title":"J Biol Chem"},{"key":"38_CR52","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/sj.ki.5001663","volume":"70","author":"N.X. Chen","year":"2006","unstructured":"Chen NX, Duan D, O\u2019Neill KD, et al.: The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 2006, 70:1046\u20131053.","journal-title":"Kidney Int"},{"key":"38_CR53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/386078a0","volume":"386","author":"G. Luo","year":"1997","unstructured":"Luo G, Ducy P, McKee MD, et al.: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386:78\u201381.","journal-title":"Nature"},{"key":"38_CR54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1083\/jcb.200402046","volume":"165","author":"M. Murshed","year":"2004","unstructured":"Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004, 165:625\u2013630.","journal-title":"J Cell Biol"},{"key":"38_CR55","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/S0021-9258(18)89439-X","volume":"260","author":"S.K. Nishimoto","year":"1985","unstructured":"Nishimoto SK, Price PA. The vitamin K-dependent bone protein is accumulated within cultured osteosarcoma cells in the presence of the vitamin K antagonist warfarin. J Biol Chem 1985, 260:2832\u20132836.","journal-title":"J Biol Chem"},{"key":"38_CR56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000088809","volume":"25","author":"D. Brancaccio","year":"2005","unstructured":"Brancaccio D, Biondi ML, Gallieni M, et al.: Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005, 25:548\u2013552.","journal-title":"Am J Nephrol"},{"key":"38_CR57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1172\/JCI17202","volume":"112","author":"C. Schafer","year":"2003","unstructured":"Schafer C, Heiss A, Schwarz A, et al.: The serum protein alpha 2-Heremans-Schmid glycoprotein\/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357\u2013366.","journal-title":"J Clin Invest"},{"key":"38_CR58","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1681\/ASN.2004100895","volume":"16","author":"J.L. Reynolds","year":"2005","unstructured":"Reynolds JL, Skepper JN, McNair R, et al.: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005, 16:2920\u20132930.","journal-title":"J Am Soc Nephrol"},{"key":"38_CR59","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(03)12710-9","volume":"361","author":"M. Ketteler","year":"2003","unstructured":"Ketteler M, Bongartz P, Westenfeld R, et al.: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003, 361:827\u2013833.","journal-title":"Lancet"},{"key":"38_CR60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000095782","volume":"26","author":"M. Cozzolino","year":"2006","unstructured":"Cozzolino M, Galassi A, Biondi ML, et al.: Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 2006, 26:423\u2013429.","journal-title":"Am J Nephrol"},{"key":"38_CR61","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/01.RES.87.11.1055","volume":"87","author":"D. Proudfoot","year":"2000","unstructured":"Proudfoot D, Skepper JN, Hegyi L, et al.: Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000, 87:1055\u20131062.","journal-title":"Circ Res"},{"key":"38_CR62","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1097\/01.ASN.0000141960.01035.28","volume":"15","author":"J.L. Reynolds","year":"2004","unstructured":"Reynolds JL, Joannides AJ, Skepper JN, et al.: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004, 15:2857\u20132867.","journal-title":"J Am Soc Nephrol"},{"key":"38_CR63","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/01.ATV.0000059406.92165.31","volume":"23","author":"K.L. Tyson","year":"2003","unstructured":"Tyson KL, Reynolds JL, McNair R, et al.: Osteo\/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003, 23:489\u2013494.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"38_CR64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<37::AID-JCP4>3.0.CO;2-M","volume":"184","author":"H. Dorai","year":"2000","unstructured":"Dorai H, Vukicevic S, Sampath TK: Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 2000, 184:37\u201345.","journal-title":"J Cell Physiol"},{"key":"38_CR65","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/BF03350814","volume":"30","author":"K.K. Doumouchtsis","year":"2007","unstructured":"Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, et al.: sRANKL\/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients. J Endocrinol Invest 2007, 30:762\u2013766.","journal-title":"J Endocrinol Invest"},{"key":"38_CR66","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1523-1755.2004.00604.x","volume":"65","author":"Y. Imanishi","year":"2004","unstructured":"Imanishi Y, Inaba M, Nakatsuka K, et al.: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004, 65:1943\u20131946.","journal-title":"Kidney Int"},{"key":"38_CR67","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1093\/ndt\/gfm347","volume":"22","author":"P.A. Westerberg","year":"2007","unstructured":"Westerberg PA, Linde T, Wikstr\u00f6m B, et al.: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007, 22:3202\u20133207.","journal-title":"Nephrol Dial Transplant"},{"key":"38_CR68","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/hmg\/ddi034","volume":"14","author":"A. Benet-Pag\u00e8s","year":"2005","unstructured":"Benet-Pag\u00e8s A, Orlik P, Strom TM, Lorenz-Depiereux B: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005, 14:385\u2013390.","journal-title":"Hum Mol Genet"},{"key":"38_CR69","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I. Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, et al.: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770\u2013774.","journal-title":"Nature"},{"key":"38_CR70","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1525-139X.2007.00308.x","volume":"20","author":"J. Stubbs","year":"2007","unstructured":"Stubbs J, Liu S, Quarles LD: Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007, 20:302\u2013308.","journal-title":"Semin Dial"},{"key":"38_CR71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ncprheum0681","volume":"4","author":"L.D. Church","year":"2008","unstructured":"Church LD, Cook GP, McDermott MF: Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008, 4:34\u201342.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"38_CR72","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.4049\/jimmunol.174.8.5016","volume":"174","author":"R. Liu-Bryan","year":"2005","unstructured":"Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R: TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005, 174:5016\u20135023.","journal-title":"J Immunol"},{"key":"38_CR73","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/art.21238","volume":"52","author":"R. Liu-Bryan","year":"2005","unstructured":"Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936\u20132946.","journal-title":"Arthritis Rheum"},{"key":"38_CR74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F. Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237\u2013241.","journal-title":"Nature"},{"key":"38_CR75","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1172\/JCI28075","volume":"116","author":"C.J. Chen","year":"2006","unstructured":"Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262\u20132271.","journal-title":"J Clin Invest"},{"key":"38_CR76","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","volume":"66","author":"D. McGonagle","year":"2007","unstructured":"McGonagle D, Tan AL, Shankaranarayana S, et al.: Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007, 66:1683\u20131684.","journal-title":"Ann Rheum Dis"},{"key":"38_CR77","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.23119","volume":"58","author":"D. McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J, et al.: Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008, 58:631\u2013633.","journal-title":"Arthritis Rheum"},{"key":"38_CR78","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ndt\/15.5.644","volume":"15","author":"O. Schreiner","year":"2000","unstructured":"Schreiner O, Wandel E, Himmelsbach F, et al.: Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant 2000, 15:644\u2013649.","journal-title":"Nephrol Dial Transplant"},{"key":"38_CR79","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.ki.5002696","volume":"73","author":"M. Schoppet","year":"2008","unstructured":"Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Exploring the biology of vascular calcification in chronic kidney disease: what\u2019s circulating? Kidney Int 2008, 73:384\u2013390.","journal-title":"Kidney Int"},{"key":"38_CR80","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/archinte.1979.03630440057019","volume":"139","author":"M.H. Ellman","year":"1979","unstructured":"Ellman MH, Brown NL, Katzenberg CA: Acute pseudogout in chronic renal failure. Arch Intern Med 1979, 139:795\u2013796.","journal-title":"Arch Intern Med"},{"key":"38_CR81","first-page":"1848","volume":"15","author":"K. Menerey","year":"1988","unstructured":"Menerey K, Braunstein E, Brown M, et al.: Musculoskeletal symptoms related to arthropathy in patients receiving dialysis. J Rheumatol 1988, 15:1848\u20131854.","journal-title":"J Rheumatol"},{"key":"38_CR82","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.joca.2003.12.004","volume":"12","author":"K. Johnson","year":"2004","unstructured":"Johnson K, Terkeltaub R: Upregulated ank expression in osteoarthritis can promote both chondrocyte MMP-13 expression and calcification via chondrocyte extracellular PPi excess. Osteoarthritis Cartilage 2004, 12:321\u2013335.","journal-title":"Osteoarthritis Cartilage"},{"key":"38_CR83","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/art.1780270402","volume":"27","author":"D. Kuntz","year":"1984","unstructured":"Kuntz D, Naveau B, Bardin T, et al.: Destructive spondylarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 1984, 27:369\u2013375.","journal-title":"Arthritis Rheum"},{"key":"38_CR84","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00296-003-0431-z","volume":"25","author":"H. Kart-K\u00f6seoglu","year":"2005","unstructured":"Kart-K\u00f6seoglu H, Yucel AE, Niron EA, et al.: Osteoarthritis in hemodialysis patients: relationships with bone mineral density and other clinical and laboratory parameters. Rheumatol Int 2005, 25:270\u2013275.","journal-title":"Rheumatol Int"},{"key":"38_CR85","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF00350536","volume":"16","author":"E.M. Braunstein","year":"1987","unstructured":"Braunstein EM, Menerey K, Martel W, et al.: Radiologic features of a pyrophosphate-like arthropathy associated with long-term dialysis. Skeletal Radiol 1987, 16:437\u2013441.","journal-title":"Skeletal Radiol"},{"key":"38_CR86","first-page":"1780","volume":"24","author":"A.J. Ferrari","year":"1997","unstructured":"Ferrari AJ, Rothfuss S, Schumacher HR Jr: Dialysis arthropathy: identification and evaluation of a subset of patients with unexplained inflammatory effusions. J Rheumatol 1997, 24:1780\u20131786.","journal-title":"J Rheumatol"},{"key":"38_CR87","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7326\/0003-4819-97-1-36","volume":"97","author":"G.S. Hoffman","year":"1982","unstructured":"Hoffman GS, Schumacher HR, Paul H, et al.: Calcium oxalate microcrystalline-associated arthritis in end-stage renal disease. Ann Intern Med 1982, 97:36\u201342.","journal-title":"Ann Intern Med"},{"key":"38_CR88","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/art.1780291112","volume":"29","author":"A.J. Reginato","year":"1986","unstructured":"Reginato AJ, Ferreiro Seoane JL, Barbazan Alvarez C, et al.: Arthropathy and cutaneous calcinosis in hemodialysis oxalosis. Arthritis Rheum 1986, 29:1387\u20131396.","journal-title":"Arthritis Rheum"},{"key":"38_CR89","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/archinte.1992.00400190135025","volume":"152","author":"J.G. Abuelo","year":"1992","unstructured":"Abuelo JG, Schwartz ST, Reginato AJ: Cutaneous oxalosis after long-term hemodialysis. Arch Intern Med 1992, 152:1517\u20131520.","journal-title":"Arch Intern Med"},{"key":"38_CR90","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0049-0172(89)90062-0","volume":"18","author":"A.J. Reginato","year":"1989","unstructured":"Reginato AJ, Kurnik B: Calcium oxalate and other crystals associated with kidney diseases and arthritis. Semin Arthritis Rheum 1989, 18:198\u2013224.","journal-title":"Semin Arthritis Rheum"},{"key":"38_CR91","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0049-0172(72)90012-1","volume":"2","author":"D.S. Newcombe","year":"1972","unstructured":"Newcombe DS: Endocrinopathies and uric acid metabolism. Semin Arthritis Rheum 1972, 2:281\u2013300.","journal-title":"Semin Arthritis Rheum"},{"key":"38_CR92","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780080304","volume":"8","author":"W.W. Buchanan","year":"1965","unstructured":"Buchanan WW, Klinenberg JR, Seegmiller JE: The inflammatory response to injected microcrystalline monosodium urate in normal, hyperuricemic, gouty, and uremic subjects. Arthritis Rheum 1965, 8:361\u2013367.","journal-title":"Arthritis Rheum"},{"key":"38_CR93","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1159\/000169131","volume":"17","author":"K. Sombolos","year":"1997","unstructured":"Sombolos K, Tsitamidou Z, Kyriazis G, et al.: Clinical evaluation of four different high-flux hemodialyzers under conventional conditions in vivo. Am J Nephrol 1997, 17:406\u2013412.","journal-title":"Am J Nephrol"},{"key":"38_CR94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000181759","volume":"25","author":"M. Mathews","year":"1980","unstructured":"Mathews M, Shen FH, Lindner A, Sherrard DJ: Septic arthritis in hemodialyzed patients. Nephron 1980, 25:87\u201391.","journal-title":"Nephron"},{"key":"38_CR95","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(72)91600-5","volume":"2","author":"R.A. Kaslow","year":"1972","unstructured":"Kaslow RA, Zellner SR: Infection in patients on maintenance haemodialysis. Lancet 1972, 2:117\u2013119.","journal-title":"Lancet"},{"key":"38_CR96","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0272-6386(03)00645-0","volume":"42","author":"M. Kurella","year":"2003","unstructured":"Kurella M, Bennett WM, Chertow GM: Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003, 42:217\u2013228.","journal-title":"Am J Kidney Dis"},{"key":"38_CR97","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","volume":"73","author":"E. Neil","year":"2006","unstructured":"Neil E, Scherrmann JM: Colchicine today. Joint Bone Spine 2006, 73:672\u2013678.","journal-title":"Joint Bone Spine"},{"key":"38_CR98","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","volume":"65","author":"W. Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E, et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1301\u20131311.","journal-title":"Ann Rheum Dis"},{"key":"38_CR99","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W. Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al.; EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312\u20131324.","journal-title":"Ann Rheum Dis"},{"key":"38_CR100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","volume":"49","author":"C.Y. Man","year":"2007","unstructured":"Man CY, Cheung IT, Cameron PA, Rainer TH: Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007, 49:670\u2013677.","journal-title":"Ann Emerg Med"},{"key":"38_CR101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"K.R. Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47\u201356.","journal-title":"Am J Med"},{"key":"38_CR102","first-page":"327","volume":"23","author":"B. Rothschild","year":"1997","unstructured":"Rothschild B, Yakubov LE: Prospective 6-month, doubleblind trial of hydroxychloroquine treatment of CPDD. Compr Ther 1997, 23:327\u2013331.","journal-title":"Compr Ther"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-008-0038-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0038-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T08:32:09Z","timestamp":1632040329000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-008-0038-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s11926-008-0038-1","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}